Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
Jansen C, Choi Y, Evans S, Greenwald R, Behnke J, Hartman C, Kissick H, Harik L, Bilen M. Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma. Frontiers In Oncology 2023, 13: 1271255. PMID: 37860195, PMCID: PMC10582703, DOI: 10.3389/fonc.2023.1271255.Peer-Reviewed Original ResearchClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSystemic therapyCell carcinomaTyrosine kinase inhibitor-targeted therapyResponse to systemic therapyWell-tolerated treatment optionCD8+T cell infiltrationCombination of immunotherapyResponse to nivolumabImmunotherapy to patientsMinimal adverse effectsVEGF-TKIDisease recurrenceCombination therapyTherapeutic regimensTherapeutic responseConsensus guidelinesTreatment optionsOptimal treatmentTumor tissuesRare typePatientsTherapy